Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 28Leukemia, Myeloid, Acute 9Neoplasms 7Lymphoma, Non-Hodgkin 7Recurrence 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Immunoglobulin Light-chain Amyloidosis 5Leukemia, Lymphocytic, Chronic, B-Cell 4Myelodysplastic Syndromes 3Amyloidosis 3Prostatic Neoplasms 2Neoplasms, Plasma Cell 2Hematologic Neoplasms 2Breast Neoplasms 2Thrombocytosis 1Small Cell Lung Carcinoma 1Proteostasis Deficiencies 1Primary Myelofibrosis 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Lymphatic Diseases 1Leukemia, Plasma Cell 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic-Phase 1

Interventions

venetoclax 1pomalidomide 1ixazomib 1daratumumab 1Dexamethasone 1Calcium Dobesilate 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Proteostasis Deficiencies × venetoclax × Plasma cell × Clear all
NCT05451771 2025-07-08

Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis

Columbia University

Phase 1/2 Recruiting
53 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Proteostasis Deficiencies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡